Hiroki Hata
About
In The Last Decade
Hiroki Hata
31 papers receiving 740 citations
Peers
Comparison fields: 5 of 82
- Genetics 318
- Molecular Biology 301
- Obstetrics and Gynecology 172
- Oncology 169
- Immunology 138
Countries citing papers authored by Hiroki Hata
This map shows the geographic impact of Hiroki Hata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroki Hata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroki Hata more than expected).
Fields of papers citing papers by Hiroki Hata
This network shows the impact of papers produced by Hiroki Hata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroki Hata. The network helps show where Hiroki Hata may publish in the future.
Co-authorship network of co-authors of Hiroki Hata
This figure shows the co-authorship network connecting the top 25 collaborators of Hiroki Hata. A scholar is included among the top collaborators of Hiroki Hata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroki Hata. Hiroki Hata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 7 | |
| 3 | 5 | |
| 4 | 15 | |
| 5 | [Efforts toward qualitative and quantitative improvements of cancer clinical trials at regional designated cancer care hospitals-through full support for cancer clinical trials by oncology pharmacy specialist and data manager]. | 1 |
| 6 | 11 | |
| 7 | 42 | |
| 8 | Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. | 6 |
| 9 | 10 | |
| 10 | 33 | |
| 11 | 46 | |
| 12 | 18 | |
| 13 | 0 | |
| 14 | 17 | |
| 15 | 13 | |
| 16 | 49 | |
| 17 | 27 | |
| 18 | 1 | |
| 19 | [Clinical significance of CA19-9 for endometriosis]. | 5 |
| 20 | 46 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.